COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH INCREASED ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY (ADCC)
The present invention is directed to a pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity (ADCC); and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine. The present invention is also directed to a method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
1 . A pharmaceutical composition comprising: (A) a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (B) a chemotherapeutic agent selected from the group consisting of: cyclophosphamide, vincristine and doxorubicine.
2 . A composition according to claim 1 wherein said type II anti-CD20 antibody is a glycoengineered, humanized B-Ly1 antibody.
3 . A composition according to claim 1 wherein said composition comprises said type II anti-CD20 antibody, cyclophosphamide and vincristine.
4 . A composition according to claim 1 wherein said composition comprises said type II anti-CD20 antibody and doxorubicine.
5 . A composition according to claim 1 wherein said composition comprises said type II anti-CD20 antibody and cyclophosphamide.
6 . A composition according to claim 1 wherein said composition comprises said type II anti-CD20 antibody, cyclophosphamide, vincristine and doxorubicine.
7 . A composition according to claim 1 comprising also a pharmaceutically-acceptable carrier.
8 . A composition according to claim 1 comprises also a corticosteroid.
9 . A composition according to claim 7 wherein said corticosteroid is prednisone.
10 . A method for the treatment of a CD20 expressing cancer, comprising administering to a patient in need of such treatment (i) an effective first amount of a type II anti-CD20 antibody with increased antibody dependent cellular cytotoxicity; and (ii) an effective second amount of one or more chemotherapeutic agents selected from the group consisting of cyclophosphamide, vincristine and doxorubicine.
11 . A method according to claim 10 wherein said second amount of chemotherapeutic agents includes cyclophosphamide and vincristine.
12 . A method according to claim 10 wherein said second amount of chemotherapeutic agents includes doxorubicine.
13 . A method according to claim 10 wherein said second amount of chemotherapeutic agents includes cyclophosphamide.
14 . A method according to claim 10 wherein said second amount of chemotherapeutic agents includes cyclophosphamide, vincristine and doxorubicine.